In this video, Motley Fool health-care analyst David Williamson takes a closer look at Sarepta's (NASDAQ:SRPT) big move on Friday. Wall Street is starting to wake up to this small biotech story and several key catalysts in the coming months could attract even more attention.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Sarepta Therapeutics Stock Doubled in 2017
Sarepta's new Duchenne muscular dystrophy drug burst onto the scene in 2017.
Here's What Caused Sarepta Therapeutics to Shoot 13% Higher In November
The company's well on its way to transforming muscular dystrophy treatment.
What Caused Sarepta Therapeutics to Rally 12.6% in September
Optimism is building for the company's potential to treat more Duchenne muscular dystrophy patients.